PMID: 15371921Sep 17, 2004Paper

Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study

European Journal of Gastroenterology & Hepatology
Xavier CalvetEmili Gené

Abstract

Eradication rates of triple therapy--a proton pump inhibitor, clarithromycin and amoxicillin twice daily for 7 days--are suboptimal in some areas of the world. Triple therapy combining ranitidine-bismuth citrate, tetracycline and metronidazole is a very effective second-line therapy. Management strategies including this treatment as first-line therapy may represent a reasonable choice. To evaluate the efficacy of a strategy combining ranitidine-bismuth citrate triple therapy followed by a proton pump inhibitor-based triple therapy for Helicobacter pylori eradication in a pilot study. One hundred and thirty-six consecutive H. pylori-positive patients were treated with 400 mg ranitidine-bismuth citrate twice daily, 500 mg tetracycline three times daily and 500 mg metronidazole three times daily for 7 days. Second-line therapy consisted of 20 mg omeprazole twice daily, 500 mg clarithromycin twice daily and 1 g amoxicillin twice daily for 7 days. The efficacy of the treatment was evaluated by histology or the urea breath test. Cure rates were 109/136 patients [80.2%; 95% confidence interval (CI), 72-86%] by intention to treat and 109/127 (85.8%; 95% CI, 78-91%) per protocol. Fifteen of the patients with treatment failure received s...Continue Reading

References

Jan 23, 1999·Gut·X Calvet, R Comet
Jan 5, 2000·BMJ : British Medical Journal·W A de Boer, G N Tytgat
Jan 13, 2000·Alimentary Pharmacology & Therapeutics·A GasbarriniG Gasbarrini
Jun 26, 2001·Alimentary Pharmacology & Therapeutics·X CalvetI Sanfeliu
Feb 28, 2002·Alimentary Pharmacology & Therapeutics·P MalfertheinerUNKNOWN European Helicobacter Pylori Study Group (EHPSG)
May 9, 2002·Enfermedades infecciosas y microbiología clínica·Eva Cuchí BurgosJavier Garau Alemany
Jul 30, 2002·Alimentary Pharmacology & Therapeutics·X CalvetUNKNOWN Group for Eradication Studies from Catalonia and Aragón (Gresca)
May 20, 2003·Alimentary Pharmacology & Therapeutics·E GenéJ P Gisbert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.